Drug reference

Dexrazoxane

Antidote · Antidote; Cardioprotective Agent; Extravasation Treatment

Also known as ZINECARD, CARDIOXANE, SAVENE

AntidoteAntidote; Cardioprotective Agent; Extravasation Treatment

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

6 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 7 →

Measles Virus Vaccine Live AttenuatedSevereDatabaseDDInter
Mumps Virus Strain B Level Jeryl Lynn Live AntigenSevereDatabaseDDInter
Rotavirus VaccineSevereDatabaseDDInter
Rubella Virus VaccineSevereDatabaseDDInter

Mechanism

Dexrazoxane is an iron chelator. Anthracyclines can form semiquinone radical intermediates that react with O2 to produce superoxide anion radicals, which generate hydrogen peroxide and hydroxyl radicals, attacking DNA. The production of free radicals is significantly stimulated by the interaction of doxorubicin with iron. Dexrazoxane chelates iron, thereby protecting against cardiac toxicity and reducing free radical formation.

Indications

Prevention of anthracycline-induced cardiotoxicityTreatment of anthracycline-induced extravasationReduction of doxorubicin-induced cardiotoxicityAmelioration of anthracycline infusion site reaction due to extravasation

Dosing

Renal adjustment: CARDIOXANE: Reduce dose by 50% if creatinine clearance less than 40 mL/minute. SAVENE: Avoid due to risk of accumulation.

Side effects

Serious

May compromise the anticancer efficacy of doxorubicin

Drug interactions

Measles Virus Vaccine Live Attenuated

Severe

Database

Clinical effect not specified

Source: DDInter

Mumps Virus Strain B Level Jeryl Lynn Live Antigen

Severe

Database

Clinical effect not specified

Source: DDInter

Rotavirus Vaccine

Severe

Database

Clinical effect not specified

Source: DDInter

Rubella Virus Vaccine

Severe

Database

Clinical effect not specified

Source: DDInter

Talimogene Laherparepvec

Severe

Database

Clinical effect not specified

Source: DDInter

Yellow Fever Vaccine

Severe

Database

Clinical effect not specified

Source: DDInter

Doxorubicin

Moderate

Database

Reduces the incidence and severity of doxorubicin-induced cardiotoxicity. However, it may also reduce the antitumor efficacy of doxorubicin in some settings.

Dexrazoxane is specifically used to mitigate doxorubicin cardiotoxicity in patients receiving high cumulative doses or those with pre-existing cardiac risk factors. Its use should be carefully weighed against potential impact on antitumor efficacy, especially in the adjuvant setting.

Source: DDInter

5 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.